menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Sapience Therapeutics to Present Posters at AACR Meeting 2025

    PR NEWSWIRE

    Sapience Presents ST316 Ph 1 Dose Data at ASCO GI Cancers Symposium

    PR NEWSWIRE

    Sapience Receives Orphan Drug Designation for ST316 in FAP

    PR NEWSWIRE

    Sapience Announces Multiple Presentations At SITC 39th Meeting

    PR NEWSWIRE

    Sapience Enrolls First Patient in Phase 2 Colorectal Cancer Study

    PR NEWSWIRE

    Sapience`s ST101 Shows Positive GBM Data, Biomarkers In ASCO Oral Session

    PR NEWSWIRE

    Sapience St101 Glioblastoma Featured: Phase 2 Clinical Biomarkers Asco

    PR NEWSWIRE

    Sapience Therapeutics Presents Three Posters at the AACR Annual Meeting 2024

    PR NEWSWIRE

    Sapience Therapeutics to Present Multiple Posters at AACR Annual Meeting 2024

    PR NEWSWIRE

    Sapience Therapeutics Presents ST101 Clinical Data and ST316 Preclinical Data

    PR NEWSWIRE

    Sapience doses first patient in trial of ST316 for solid tumours

    CLINICAL TRIALS ARENA

    Sapience Announces First Patient Dosed in Phase 1-2 Clinical Study of ST316

    PR NEWSWIRE

    Sapience to Present Late-Breaking Data on ST101 and ST316 at AACR

    PR NEWSWIRE

    Sapience Announces Research Poster Presentations on ST101 and ST316

    PR NEWSWIRE

    Sapience Receives IND Clearance from FDA to Proceed with Ph 1-2 Study of ST316

    PR NEWSWIRE

    Sapience Presents Data on the Immune Activating Function of ST101 at(SITC)

    PRNEWSWIRE

    Sapience Announces Presentation on the Immune Activating Function of ST101

    PRNEWSWIRE

    Sapience Therapeutics Awarded SBIR Phase 2 Grant from NCI of the NIH for ST101

    PRNEWSWIRE

    Sapience Tx Announces Surgical Sub-Study of Ongoing Phase 1-2 Trial of ST101

    PRNEWSWIRE

    Sapience Therapeutics Announces Expansion of PII Study Arm with ST101

    PRNEWSWIRE

    Peptide biotech gets renewed support from Bristol Myers and others

    ENDPTS

    Sapience Therapeutics Announces Poster Presentation on ST101 PI Results

    PRNEWSWIRE

    Sapience Presents Data at AACR 2022 for Targeting Intracellular Interactions

    PRNEWSWIRE

    Sapience Therapeutics Expands Executive Team; Appoints VP, Regulatory Affairs

    PRNEWSWIRE

    Sapience Tx Announces Multiple Poster Presentations at AACR 2022

    PRNEWSWIRE

    Sapience Therapeutics Doses First Patient in Phase 2 Clinical Trial of ST101

    PRNEWSWIRE

    Sapience Therapeutics Announces Multiple Poster Presentations on ST101

    PRNEWSWIRE

    Sapience Therapeutics Awarded SBIR Grant from National Cancer Institute (NCI)

    PRNEWSWIRE

    Sapience Enters Into Collaboration with National Cancer Institute (NCI)

    PRNEWSWIRE

    Sapience Enters Into Collaboration with National Cancer Institute (NCI) ST101

    PRNEWSWIRE

    Sapience Announces Multiple Posters, Including Late-Breaker, at the American

    PRNEWSWIRE

    Sapience Therapeutics Announces First Patient Dosed with ST101 in Ph 1/2 Study

    ACCESSWIRE

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.